生物和治疗罕见疾病合作加速杜申肌肉发育不良症的基因治疗,使用人工智能,提高制造效率从13%提高到59%. Form Bio and Cure Rare Disease partnered to accelerate gene therapy for Duchenne muscular dystrophy using AI, boosting manufacturing efficiency from 13% to 59%.

生物和治愈性疾病(CRD)结成了伙伴关系,以加速发展稀有神经肌肉疾病的基因疗法,首先是杜尚氏肌肉萎缩症。 Form Bio and Cure Rare Disease (CRD) have formed a partnership to speed up development of gene therapies for rare neuromuscular diseases, beginning with Duchenne muscular dystrophy (DMD). 这些团队使用表格Bio的AI-动力平台,在一个月内将全长AAV矢量的比例从13%提高到59%,大大提高了制造业效率和治疗安全。 Using Form Bio’s AI-powered platform, the teams boosted the proportion of full-length AAV vectors from 13% to 59% in one month, significantly improving manufacturing efficiency and therapy safety. 这一进步使CRD能够更有信心地将其DMD候选人转到现场临床前测试中。 This advance enables CRD to move its DMD candidate into in vivo preclinical testing with greater confidence. 合作将非营利性任务驱动的研究与AI驱动的生物技术创新结合起来,以减少发展时间、成本和风险,目的是向选择很少或根本没有选择的病人提供治疗。 The collaboration combines nonprofit mission-driven research with AI-driven biotech innovation to reduce development time, cost, and risk, aiming to deliver treatments for patients with few or no options.